Adhesive capsulitis (AC) is painful and disabling condition that is associated with a gradual loss of shoulder motion. Intra-articular steroid injection is a common treatment in the initial painful stage of AC, and its use in combination with hyaluronidase may offer increased therapeutic efficacy owing to synergistic effects. We determined the therapeutic efficiency of the co-administration of hyaluronidase in early AC by evaluating symptomatic, anthropometric, and imaging changes.
We enrolled eligible patients with primary adhesive capsulitis in the initial stage.The subjects were randomly assigned into 3 groups to receive ultrasound-guided intra-articular injections with 20 mg (group A) and 40 mg triamcinolone acetonide (group B) and 20 mg acetonide combined with hyaluronidase (group C). The outcome measures included the visual analogue scale (VAS), the shoulder disability questionnaire (SDQ), abduction and external rotation range of motion, and intra-sheath fluid (ISF) before treatment and at 2, 4, 8, and 16 weeks after treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
30
We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
Veterans Health Service Medical Center
Seoul, South Korea
Change of visual analogue scale (VAS)
Evaluation for the change of VAS that means average degree of shoulder pain for 24 hours before the evaluation (from 0 to 10 points)
Time frame: Evaluation at 5 time intervals: before injection and at 2, 4, 8, and 16 weeks after the injection
Change of shoulder disability questionnaire (SDQ)
Evaluation for the change of SDQ that means the self-reported functional status in patients with shoulder disorders, comprised of 16 questions, reflecting the pain during various movements related with activities of daily living, with scores ranging from 0 (no disability) to 16 (greatest possible disability).
Time frame: Evaluation at 5 time intervals: before injection and at 2, 4, 8, and 16 weeks after the injection
Change of degree for the abduction motion of shoulder
Evaluation for the change of degree for the motion of shoulder, checked with an inclinometer, as a passive maneuver, in the supine position
Time frame: Evaluation at 5 time intervals: before injection and at 2, 4, 8, and 16 weeks after the injection
Change of degree for the flexion motion of shoulder
Evaluation for the change of degree for the motion of shoulder, checked with an inclinometer, as a passive maneuver, in the supine position
Time frame: Evaluation at 5 time intervals: before injection and at 2, 4, 8, and 16 weeks after the injection
Change of area for the intra-sheath fluid
Evaluation for the change of area for the intra-sheath fluid, checked and calculated ultrasonographically at the upper portion of the bicipital groove of the humerus.
Time frame: Evaluation at 5 time intervals: before injection and at 2, 4, 8, and 16 weeks after the injection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.